ANI director sells 13,973 shares in two trades

ANI Pharmaceuticals director Patrick D. Walsh reported selling Common Stock in two open-market transactions.

(High)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ANI Pharmaceuticals director Patrick D. Walsh reported selling Common Stock in two open-market transactions. On May 13, he sold 10,000 shares at an average price of $80.63 per share. On May 11, he sold an additional 3,973 shares at an average price of $80.75 per share. After these sales totaling 13,973 shares, Walsh directly holds 38,432 shares of ANI Pharmaceuticals Common Stock.

Insider Trade Summary

Net Seller: 13,973 shares

Net Sell 2 txns

Insider Walsh Patrick D

Role Director

Sold 13,973 shs ($1.13M)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$80.63	$806K
Sale	Common Stock	3,973	$80.75	$321K

Holdings After Transaction: Common Stock — 38,432 shares (Direct)

Key Figures

Shares sold May 13: 10,000 shares Price May 13 sale: $80.63/share Shares sold May 11: 3,973 shares +3 more

6 metrics

Shares sold May 13 10,000 shares Open-market sale of Common Stock at $80.63 per share

Price May 13 sale $80.63/share Average sale price for 10,000 Common Stock shares

Shares sold May 11 3,973 shares Open-market sale of Common Stock at $80.75 per share

Price May 11 sale $80.75/share Average sale price for 3,973 Common Stock shares

Total shares sold 13,973 shares Combined open-market Common Stock sales in May

Shares held after transactions 38,432 shares Direct Common Stock ownership after reported sales

Key Terms

open-market sale, Common Stock, transaction code, net-sell

4 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

transaction code financial

"transaction_code": "S""

net-sell financial

"netBuySellDirection": "net-sell""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ANI Pharmaceuticals (ANIP) disclose in this Form 4?

ANI Pharmaceuticals director Patrick D. Walsh disclosed two open-market sales of Common Stock totaling 13,973 shares, executed on May 11 and May 13 at prices around $80 per share.

How many ANI Pharmaceuticals (ANIP) shares did Patrick D. Walsh sell and at what prices?

Patrick D. Walsh sold 10,000 shares at $80.63 per share on May 13 and 3,973 shares at $80.75 per share on May 11, for total reported sales of 13,973 shares.

What is Patrick D. Walsh’s remaining stake in ANI Pharmaceuticals (ANIP) after these sales?

Following the reported open-market sales, Patrick D. Walsh directly holds 38,432 shares of ANI Pharmaceuticals Common Stock, as shown in the post-transaction ownership reported in the Form 4.

Were the ANI Pharmaceuticals (ANIP) insider transactions open-market sales?

Yes. Both transactions reported by director Patrick D. Walsh are coded as “S” and described as open-market or private sales of Common Stock, indicating discretionary sale transactions rather than option exercises or tax withholdings.

Does this ANI Pharmaceuticals (ANIP) Form 4 show any option exercises or derivative positions?

The Form 4 shows no derivative transactions or option exercises for Patrick D. Walsh. The derivativeSummary section is empty, and both reported transactions involve non-derivative Common Stock sales only.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/13/2026 - 08:22 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walsh Patrick D

(Last)

(First)

(Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON

NEW JERSEY

08540

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/11/2026		S		3,973	D	$80.75	48,432	D
Common Stock	05/13/2026		S		10,000	D	$80.63	38,432	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

	/s/ Patrick D. Walsh, by attorney-in-fact Meredith W. Cook	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR